Literature DB >> 22865690

Proinflammatory cytokine regulation of cyclic AMP-phosphodiesterase 4 signaling in microglia in vitro and following CNS injury.

Mousumi Ghosh1, Daniela Garcia-Castillo, Vladimir Aguirre, Roozbeh Golshani, Coleen M Atkins, Helen M Bramlett, W Dalton Dietrich, Damien D Pearse.   

Abstract

Cyclic AMP suppresses immune cell activation and inflammation. The positive feedback loop of proinflammatory cytokine production and immune activation implies that cytokines may not only be regulated by cyclic AMP but also conversely regulate cyclic AMP. This study examined the effects of tumor necrosis factor (TNF)-α and interleukin (IL)-1β on cyclic AMP-phosphodiesterase (PDE) signaling in microglia in vitro and after spinal cord injury (SCI) or traumatic brain injury (TBI). TNF-α or IL-1β stimulation produced a profound reduction (>90%) of cyclic AMP within EOC2 microglia from 30 min that then recovered after IL-1β but remained suppressed with TNF-α through 24 h. Cyclic AMP was also reduced in TNF-α-stimulated primary microglia, albeit to a lesser extent. Accompanying TNF-α-induced cyclic AMP reductions, but not IL-1β, was increased cyclic AMP-PDE activity. The role of PDE4 activity in cyclic AMP reductions was confirmed by using Rolipram. Examination of pde4 mRNA revealed an immediate, persistent increase in pde4b with TNF-α; IL-1β increased all pde4 mRNAs. Immunoblotting for PDE4 showed that both cytokines increased PDE4A1, but only TNF-α increased PDE4B2. Immunocytochemistry revealed PDE4B nuclear translocation with TNF-α but not IL-1β. Acutely after SCI/TBI, where cyclic AMP levels are reduced, PDE4B was localized to activated OX-42(+) microglia; PDE4B was absent in OX-42(+) cells in uninjured spinal cord/cortex or inactive microglia. Immunoblotting showed PDE4B2 up-regulation from 24 h to 1 wk post-SCI, the peak of microglia activation. These studies show that TNF-α and IL-1β differentially affect cyclic AMP-PDE signaling in microglia. Targeting PDE4B2 may be a putative therapeutic direction for reducing microglia activation in CNS injury and neurodegenerative diseases.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22865690      PMCID: PMC4383287          DOI: 10.1002/glia.22401

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  72 in total

1.  Inhibition of tumour necrosis factor-alpha by antisense targeting produces immunophenotypical and morphological changes in injury-activated microglia and macrophages.

Authors:  Damien D Pearse; Francisco C Pereira; Anna Stolyarova; David J Barakat; Mary Bartlett Bunge
Journal:  Eur J Neurosci       Date:  2004-12       Impact factor: 3.386

2.  Expression of pro-inflammatory cytokine and chemokine mRNA upon experimental spinal cord injury in mouse: an in situ hybridization study.

Authors:  D Bartholdi; M E Schwab
Journal:  Eur J Neurosci       Date:  1997-07       Impact factor: 3.386

3.  Prostaglandin E receptor subtypes in cultured rat microglia and their role in reducing lipopolysaccharide-induced interleukin-1beta production.

Authors:  A O Caggiano; R P Kraig
Journal:  J Neurochem       Date:  1999-02       Impact factor: 5.372

4.  Jun, Fos and Krox in the thalamus after C-fiber stimulation: coincident-input-dependent expression, expression across somatotopic boundaries, and nucleolar translocation.

Authors:  D D Pearse; G Bushell; J D Leah
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

5.  Characterization of the early neuroinflammation after spinal cord injury in mice.

Authors:  Tiffany Rice; Jennifer Larsen; Serge Rivest; V Wee Yong
Journal:  J Neuropathol Exp Neurol       Date:  2007-03       Impact factor: 3.685

6.  Tumor necrosis factor-alpha activates nuclear factor kappa B and induces manganous superoxide dismutase and phosphodiesterase mRNA in human papillary thyroid carcinoma cells.

Authors:  X P Pang; N S Ross; M Park; G J Juillard; T M Stanley; J M Hershman
Journal:  J Biol Chem       Date:  1992-06-25       Impact factor: 5.157

7.  Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis.

Authors:  Elisabet Reyes-Irisarri; Antonio J Sánchez; Juan Antonio García-Merino; Guadalupe Mengod
Journal:  J Neuropathol Exp Neurol       Date:  2007-10       Impact factor: 3.685

Review 8.  Cyclic AMP: master regulator of innate immune cell function.

Authors:  Carlos H Serezani; Megan N Ballinger; David M Aronoff; Marc Peters-Golden
Journal:  Am J Respir Cell Mol Biol       Date:  2008-03-06       Impact factor: 6.914

9.  Regulation of T-cell activation by phosphodiesterase 4B2 requires its dynamic redistribution during immunological synapse formation.

Authors:  Jacqueline Arp; Mark G Kirchhof; Miren L Baroja; Steven H Nazarian; Thu A Chau; Craig A Strathdee; Eric H Ball; Joaquín Madrenas
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

10.  The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells.

Authors:  J Semmler; H Wachtel; S Endres
Journal:  Int J Immunopharmacol       Date:  1993-04
View more
  31 in total

Review 1.  Phosphodiesterase inhibitors as therapeutics for traumatic brain injury.

Authors:  David J Titus; Anthony A Oliva; Nicole M Wilson; Coleen M Atkins
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

2.  Neuroprotective effects of roflumilast against quinolinic acid-induced rat model of Huntington's disease through inhibition of NF-κB mediated neuroinflammatory markers and activation of cAMP/CREB/BDNF signaling pathway.

Authors:  Priyanka Saroj; Yashika Bansal; Raghunath Singh; Ansab Akhtar; Rupinder Kaur Sodhi; Mahendra Bishnoi; Sangeeta Pilkhwal Sah; Anurag Kuhad
Journal:  Inflammopharmacology       Date:  2021-01-31       Impact factor: 4.473

3.  Phosphodiesterase 4b expression plays a major role in alcohol-induced neuro-inflammation.

Authors:  Diana V Avila; Scott A Myers; JingWen Zhang; Giorgi Kharebava; Craig J McClain; Hee-Yong Kim; Scott R Whittemore; Leila Gobejishvili; Shirish Barve
Journal:  Neuropharmacology       Date:  2017-08-12       Impact factor: 5.250

4.  Microglial autophagy defect causes parkinson disease-like symptoms by accelerating inflammasome activation in mice.

Authors:  Jinbo Cheng; Yajin Liao; Yuan Dong; Han Hu; Nannan Yang; Xiangxi Kong; Shuoshuo Li; Xiaoheng Li; Jifeng Guo; Lixia Qin; Jiezhong Yu; Cungen Ma; Jianke Li; Mingtao Li; Beisha Tang; Zengqiang Yuan
Journal:  Autophagy       Date:  2020-01-31       Impact factor: 16.016

5.  Involvement of IL-17 in Secondary Brain Injury After a Traumatic Brain Injury in Rats.

Authors:  Tan Li; Yong-Mei Zhang; Dong Han; Rong Hua; Bing-Nan Guo; Shu-Qun Hu; Xian-Liang Yan; Tie Xu
Journal:  Neuromolecular Med       Date:  2017-09-15       Impact factor: 3.843

6.  Apremilast Alters Behavioral Responses to Ethanol in Mice: I. Reduced Consumption and Preference.

Authors:  Yuri A Blednov; Adriana J Da Costa; Tamara Tarbox; Olga Ponomareva; Robert O Messing; R Adron Harris
Journal:  Alcohol Clin Exp Res       Date:  2018-03-24       Impact factor: 3.455

7.  Following spinal cord injury, PDE4B drives an acute, local inflammatory response and a chronic, systemic response exacerbated by gut dysbiosis and endotoxemia.

Authors:  Scott A Myers; Leila Gobejishvili; Sujata Saraswat Ohri; C Garrett Wilson; Kariena R Andres; Amberly S Riegler; Hridgandh Donde; Swati Joshi-Barve; Shirish Barve; Scott R Whittemore
Journal:  Neurobiol Dis       Date:  2018-12-14       Impact factor: 5.996

Review 8.  Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease.

Authors:  Mark E Gurney; Emily C D'Amato; Alex B Burgin
Journal:  Neurotherapeutics       Date:  2015-01       Impact factor: 7.620

9.  Ferulic acid prevents LPS-induced up-regulation of PDE4B and stimulates the cAMP/CREB signaling pathway in PC12 cells.

Authors:  Hao Huang; Qian Hong; Hong-Ling Tan; Cheng-Rong Xiao; Yue Gao
Journal:  Acta Pharmacol Sin       Date:  2016-09-26       Impact factor: 6.150

10.  Gastroprotective effect of cilostazol against ethanol- and pylorus ligation-induced gastric lesions in rats.

Authors:  Helmy Moawad; Sally A El Awdan; Nada A Sallam; Wafaa I El-Eraky; Mohammed A Alkhawlani
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-08-01       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.